For research use only. Not for therapeutic Use.
AB-836 is an orally active HBV capsid inhibitor. AB-836 inhibits viral replication by interacting with HBV core protein[1].
| Catalog Number | I042624 |
| CAS Number | 2445597-31-7 |
| Synonyms | 3-(3-cyano-4-fluorophenyl)-1-[(1R)-1-(6,7-difluoro-1-oxo-2H-isoquinolin-4-yl)ethyl]-1-methylurea |
| Molecular Formula | C20H15F3N4O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H15F3N4O2/c1-10(15-9-25-19(28)14-7-18(23)17(22)6-13(14)15)27(2)20(29)26-12-3-4-16(21)11(5-12)8-24/h3-7,9-10H,1-2H3,(H,25,28)(H,26,29)/t10-/m1/s1 |
| InChIKey | WKCMLORRPISTPL-SNVBAGLBSA-N |
| SMILES | CC(C1=CNC(=O)C2=CC(=C(C=C21)F)F)N(C)C(=O)NC3=CC(=C(C=C3)F)C#N |
| Reference | [1]. Elisabetta Degasperi, et al. Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies. Viruses 2022, 14(11), 2404. |
